Browse APRT

Summary
SymbolAPRT
Nameadenine phosphoribosyltransferase
Aliases AMP diphosphorylase; AMP pyrophosphorylase; transphosphoribosidase
Chromosomal Location16q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm.
Domain PF00156 Phosphoribosyl transferase domain
Function

Catalyzes a salvage reaction resulting in the formation of AMP, that is energically less costly than de novo synthesis.

> Gene Ontology
 
Biological Process GO:0006144 purine nucleobase metabolic process
GO:0006164 purine nucleotide biosynthetic process
GO:0006166 purine ribonucleoside salvage
GO:0006167 AMP biosynthetic process
GO:0006168 adenine salvage
GO:0007589 body fluid secretion
GO:0007595 lactation
GO:0007625 grooming behavior
GO:0009112 nucleobase metabolic process
GO:0009113 purine nucleobase biosynthetic process
GO:0009116 nucleoside metabolic process
GO:0009119 ribonucleoside metabolic process
GO:0009123 nucleoside monophosphate metabolic process
GO:0009124 nucleoside monophosphate biosynthetic process
GO:0009126 purine nucleoside monophosphate metabolic process
GO:0009127 purine nucleoside monophosphate biosynthetic process
GO:0009150 purine ribonucleotide metabolic process
GO:0009152 purine ribonucleotide biosynthetic process
GO:0009156 ribonucleoside monophosphate biosynthetic process
GO:0009161 ribonucleoside monophosphate metabolic process
GO:0009163 nucleoside biosynthetic process
GO:0009165 nucleotide biosynthetic process
GO:0009167 purine ribonucleoside monophosphate metabolic process
GO:0009168 purine ribonucleoside monophosphate biosynthetic process
GO:0009260 ribonucleotide biosynthetic process
GO:0030879 mammary gland development
GO:0032261 purine nucleotide salvage
GO:0032868 response to insulin
GO:0032869 cellular response to insulin stimulus
GO:0032941 secretion by tissue
GO:0042278 purine nucleoside metabolic process
GO:0042440 pigment metabolic process
GO:0042451 purine nucleoside biosynthetic process
GO:0042455 ribonucleoside biosynthetic process
GO:0043094 cellular metabolic compound salvage
GO:0043096 purine nucleobase salvage
GO:0043101 purine-containing compound salvage
GO:0043173 nucleotide salvage
GO:0043174 nucleoside salvage
GO:0043434 response to peptide hormone
GO:0044209 AMP salvage
GO:0044708 single-organism behavior
GO:0046033 AMP metabolic process
GO:0046083 adenine metabolic process
GO:0046084 adenine biosynthetic process
GO:0046112 nucleobase biosynthetic process
GO:0046128 purine ribonucleoside metabolic process
GO:0046129 purine ribonucleoside biosynthetic process
GO:0046148 pigment biosynthetic process
GO:0046390 ribose phosphate biosynthetic process
GO:0048732 gland development
GO:0050878 regulation of body fluid levels
GO:0071375 cellular response to peptide hormone stimulus
GO:0071417 cellular response to organonitrogen compound
GO:0072522 purine-containing compound biosynthetic process
GO:1901293 nucleoside phosphate biosynthetic process
GO:1901652 response to peptide
GO:1901653 cellular response to peptide
GO:1901657 glycosyl compound metabolic process
GO:1901659 glycosyl compound biosynthetic process
Molecular Function GO:0002054 nucleobase binding
GO:0002055 adenine binding
GO:0002060 purine nucleobase binding
GO:0003999 adenine phosphoribosyltransferase activity
GO:0016208 AMP binding
GO:0016757 transferase activity, transferring glycosyl groups
GO:0016763 transferase activity, transferring pentosyl groups
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa00230 Purine metabolism
hsa01100 Metabolic pathways
Reactome R-HSA-168256: Immune System
R-HSA-168249: Innate Immune System
R-HSA-1430728: Metabolism
R-HSA-15869: Metabolism of nucleotides
R-HSA-6798695: Neutrophil degranulation
R-HSA-73847: Purine metabolism
R-HSA-74217: Purine salvage
Summary
SymbolAPRT
Nameadenine phosphoribosyltransferase
Aliases AMP diphosphorylase; AMP pyrophosphorylase; transphosphoribosidase
Chromosomal Location16q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between APRT and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolAPRT
Nameadenine phosphoribosyltransferase
Aliases AMP diphosphorylase; AMP pyrophosphorylase; transphosphoribosidase
Chromosomal Location16q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of APRT in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NS NA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell logFC: -2.83; FDR: 0.01650 Resistant to T cell-mediated killing
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NS NA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NS NA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NS NA/NS
24476824shRNAmelanomaB16Primary screen NA/NS NA/NS
24476824shRNAmelanomaB16Secondary screen NA/NS NA/NS
Summary
SymbolAPRT
Nameadenine phosphoribosyltransferase
Aliases AMP diphosphorylase; AMP pyrophosphorylase; transphosphoribosidase
Chromosomal Location16q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of APRT in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3940.183
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1740.959
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.5610.811
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1830.739
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0690.969
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5020.822
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.1090.785
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.5330.726
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.2940.868
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 48-0.0450.985
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.5510.879
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.0090.913
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of APRT in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.71.42.30.469
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.71.720.532
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38270001
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22130001
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolAPRT
Nameadenine phosphoribosyltransferase
Aliases AMP diphosphorylase; AMP pyrophosphorylase; transphosphoribosidase
Chromosomal Location16q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of APRT. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolAPRT
Nameadenine phosphoribosyltransferase
Aliases AMP diphosphorylase; AMP pyrophosphorylase; transphosphoribosidase
Chromosomal Location16q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of APRT. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by APRT.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolAPRT
Nameadenine phosphoribosyltransferase
Aliases AMP diphosphorylase; AMP pyrophosphorylase; transphosphoribosidase
Chromosomal Location16q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of APRT. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolAPRT
Nameadenine phosphoribosyltransferase
Aliases AMP diphosphorylase; AMP pyrophosphorylase; transphosphoribosidase
Chromosomal Location16q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of APRT expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolAPRT
Nameadenine phosphoribosyltransferase
Aliases AMP diphosphorylase; AMP pyrophosphorylase; transphosphoribosidase
Chromosomal Location16q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between APRT and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolAPRT
Nameadenine phosphoribosyltransferase
Aliases AMP diphosphorylase; AMP pyrophosphorylase; transphosphoribosidase
Chromosomal Location16q24
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting APRT collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting APRT.
ID Name Drug Type Targets #Targets
DB00173AdenineSmall MoleculeACACB, ACP1, APRT, MTAP, PECR, SRPK26
DB01632Alpha-Phosphoribosylpyrophosphoric AcidSmall MoleculeAPRT, HPRT1, UCKL13
DB035069-DeazaadenineSmall MoleculeAPRT1
DB04272Citric AcidSmall MoleculeAKR1B1, ANG, APRT, BHMT, C8G, CPB1, CS, CTDSP1, GNMT, HGS, HS3ST3A ......23